Substance Use Disorder Insurance Denial Appeals
Insurers frequently deny IOP and residential substance use disorder treatment on medical-necessity or benefit-maximum grounds. Where a plan covers comparable medical/surgical care without the same restriction, that asymmetry is the core of an MHPAEA parity appeal.
Full substance use disorder appeal guide
Addiction Treatment Insurance Denials: Appealing IOP and Residential Coverage Under MHPAEA
Common denial codes for substance use disorder
Appeal by payer
Generate your substance use disorder appeal letter in minutes
Therapists get 5 free letters every month. Appealing your own denial? It's $19 per letter, one-time. MHPAEA arguments included when applicable.
Generate my appeal letter →Frequently asked questions about substance use disorder appeals
Does MHPAEA cover substance use disorder residential treatment specifically?
Yes, for plans MHPAEA covers. Residential SUD treatment is a recognized level of care under the parity framework — the appeal question is whether the plan's medical necessity or authorization criteria for that level of care are applied more restrictively than for comparable medical/surgical care.
What is the difference between MCG Guidelines and ASAM criteria?
Payers often use proprietary utilization-management guidelines (like MCG) to evaluate SUD level-of-care requests, while treating clinicians typically document using ASAM criteria. When the two produce different outcomes, requesting the payer's written comparative analysis of how its criteria compare to medical/surgical benefits is a standard next step.
What if the plan denies a comparative analysis request?
CAA 2021 § 203 (29 U.S.C. § 1185a(a)(8)) requires plans to produce a written NQTL comparative analysis on request. A failure to produce it, or an inadequate response, can itself be documented as part of the appeal record.